8-β-D-グルコピラノシル-3-(4-ヒドロキシフェニル)-7-ヒドロキシ-4H-1-ベンゾピラン-4-オン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

8-β-D-グルコピラノシル-3-(4-ヒドロキシフェニル)-7-ヒドロキシ-4H-1-ベンゾピラン-4-オン 価格

8-β-D-グルコピラノシル-3-(4-ヒドロキシフェニル)-7-ヒドロキシ-4H-1-ベンゾピラン-4-オン 化学特性,用途語,生産方法

• 外観

  白色の結晶又は結晶性の粉末

• 溶解性

  メタノールに溶けやすく、エタノール(99.5)にやや溶けやすく、水にほとんど溶けない。

• 説明

  Puerarin, also known as pueraria flavonoids, is a kind of flavonoid glycoside extracted from the roots of Pueraria alba or Pueraria thomsonii and is also one of the main effective ingredients of Pueraria lobata. That Pueraria lobate was used to treat diseases has already been recorded in China’s ancient medical books such as Shen Nong’s Materia Medica, Treatise on Miscellaneous Diseases and Medical Dictionary.
  Kanzu root is widely distributed in our country and of rich resources. It has been reported that puerarin could be extracted from Pueraria lobata (Wild.) Ohwi, Radix Pueraria thomsonii, Pueraria omeiensiswanget Tang, Pueraria edulis Pamp and Pueraria phaseoloides, but the content of puerarin differs.
  Pueraria has a great value for nutrition and medicine and was considered the south ginseng of China. Puerarin has been widespread concerned over our country for its use of food and medicine in recent years.
  

• 化学的特性

  White powder

• 物理的性質

  Appearance: White to light-yellow crystalline powder. Solubility: Soluble in methanol, freely soluble in ethanol, slightly soluble in water, insoluble in chloroform and ether. Melting point: 187–189?°C.

• 来歴

  In 1959, Japanese chemist Shibata Shoji first studied the chemical production of pueraria root, indicating that isoflavones are the main active ingredients of pueraria root, including puerarin, daidzin and daidzein . Then in 2003, David Lee first total synthesized analogical puerarin . And it was in 1974 that puerarin was first extracted by Fang Qicheng and other chemists in China . Due to its strong activity of anti-cardiovascular and anti-cerebrovascular ischemia and hypoxia, expanding the coronary artery and cerebrovascular, reducing myocardial oxygen consumption, and improving myocardial systolic and microcirculation function, puerarin was approved for clinical use by the Ministry of Health in 1993.
  In recent years, researchers have synthesized a series of puerarin derivatives, and active research showed that the part of the puerarin derivatives has a good biological activity and bioavailability. In a new dosage form research, researchers have developed several types of dosage forms such as quickrelease solid dispersions, solid from microemulsion preparation, etc., which greatly increase the solubility of puerarin, thus improving bioavailability. In recent years,the research on crystal drug has opened up new ways for the application of puerarin.

• 使用

  Puerarin is a naturally occuring isoflavonoid derived from Chinese medical herb kudzu root and has been used for the treatment of various cardiovascular diseases. Recent sutdies have shown the potenti al of puerarin treatment as a novel approach to lowering the risk of or improving function in ischemia-reperfusion brain injury-related disorders.

• 適応症

  At present the most widely used medicinal formulation of puerarin in clinical application is puerarin injection, with more than 90 enterprises producing it. The injection was mainly used for the treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal movement, vein occlusion, sudden deafness and other diseases. Another dosage form of puerarin is eye drops for the treatment of primary open-angle glaucoma, ocular hypertension, primary angle closure glaucoma and secondary glaucoma. In addition, there are puerarin tablets and puerarin capsules, belonging to the health-care product.

• 定義

  ChEBI: A hydroxyisoflavone that is isoflavone substituted by hydroxy groups at positions 7 and 4' and a beta-D-glucopyranosyl residue at position 8 via a C-glycosidic linkage.

• 薬理学

  Contemporary pharmacological research has demonstrated that puerarin has wide pharmacological activities on the cardiovascular system, nervous system, liver impairments, osteoporosis and hangover .
  The clinical and experimental researches have shown that puerarin has a significant role in the prevention of cerebral vascular disease, which can expand the coronary artery and improve the metabolism of an ischemic heart muscle, improving brain circulation, increasing cerebral blood flow and reducing blood volume and heart rate. There is good control of puerarin on myocardial ischemia and cerebral ischemic disease.
  A large number of experiments have proved that puerarin can promote the glucose and lipid metabolism and reduce blood sugar and blood lipid. The protection of puerarin on diabetes was attributed to its functions on inhibiting apoptosis and oxidative stress.
  Puerarin have protection efficacy on liver damage induced by chemical substances, alcohol, surgery and other experimental damage. This effect is closely related to the antioxidant effect, resisting lipid peroxidation, inhibiting platelet aggregation and improving circulation.
  Puerarin can also improve the eye microcirculation obviously and reduce the pressure of the eyes, thus acting obvious therapeutic effect on glaucoma. In addition, it has a variety of preparations, such as liquors, which are still under development.

• 臨床応用

  Currently, puerarin is used clinically for the treatment of hypertension, coronary heart disease, angina pectoris, arrhythmia, myocardial infarction, ischemic cerebrovascular disease, retinal arteriovenous obstruction, sudden deafness, diabetes complications, dizziness and other diseases. Besides, it also is used to treat chronic pharyngitis, cerebral infarction and Parkinson’s syndrome.
  However, puerarin also has adverse reactions in clinical therapy. Fever is the main symptom. In addition, allergic dermatitis, anaphylactic shock, laryngeal oedema, increased transaminase, gastrointestinal bleeding, haemolysis phenomenon and kidney damage occurred occasionally, and these symptoms disappeared after withdrawal of the medication.

8-β-D-グルコピラノシル-3-(4-ヒドロキシフェニル)-7-ヒドロキシ-4H-1-ベンゾピラン-4-オン 上流と下流の製品情報

8-β-D-グルコピラノシル-3-(4-ヒドロキシフェニル)-7-ヒドロキシ-4H-1-ベンゾピラン-4-オン 生産企業

Global(608)Suppliers

8-β-D-グルコピラノシル-3-(4-ヒドロキシフェニル)-7-ヒドロキシ-4H-1-ベンゾピラン-4-オン スペクトルデータ(¹HNMR)

3681-99-0, 8-β-D-グルコピラノシル-3-(4-ヒドロキシフェニル)-7-ヒドロキシ-4H-1-ベンゾピラン-4-オン キーワード